Clin Pediatr Hematol Oncol.  2022 Apr;29(1):21-24. 10.15264/cpho.2022.29.1.21.

A Rare Case of Acquired Hemophilia A in Adolescents and Young Adults

• Lee MJ
• Park YS

• KMID: 2529688
• DOI: http://doi.org/10.15264/cpho.2022.29.1.21

Abstract

Acquired hemophilia A (AHA) is a rare bleeding disorder, especially in adolescents and young adults (AYAs) attributable to the development of autoantibodies against coagulation factor VIII (FVIII). AHA diagnosis is difficult; patients lack any history of coagulopathy. We report here on an AYA with AHA who responded well to treatment. A 19-year-old woman visited our hospital with painful swelling of the right lower leg. She had no past or familial history of a bleeding disorder. The initial laboratory data revealed a prolonged activated partial thromboplastin time and an uncorrected mixing test result. The FVIII activity was below 1% and the FVIII antibody level 22.4 Bethesda units. She was diagnosed with AHA and treated with recombinant activated coagulation factor VII, activated prothrombin complex concentrates and an oral steroid. After 9 months, FVIII antibody level was negative and the FVIII activity was normalized. AHA is very rare especially in AYAs, but physicians must be suspicious about the disorder and plan specialized coagulation tests to diagnose the disease. An early diagnosis of acquired bleeding disorders should be done for initiating the adequate treatment immediately by both controlling the acute bleeding episode and eliminating FVIII antibodies.

Keyword

Hemophilia A; Acquired hemophilia A; Coagulation factor VIII; Autoantibodies; Immunosuppressive treatment